NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
Clinical Trials
13 trialsNCT03963518 2025-10-06
SURROGATE-ICI
Institut Bergonié
Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03570619 2025-05-08
IMPACT
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03296137 2024-10-26
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
Phase 1/2 Completed
NCT02467361 2023-11-14
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02904226 2023-07-03
ICONIC
Jounce Therapeutics, Inc.
Phase 1/2 Completed
NCT03453892 2023-02-16
ST-ICI
University of Erlangen-Nürnberg Medical School
Completed
NCT02977156 2022-07-25
ISI-JX
Centre Leon Berard
Phase 1 Completed
NCT03525795 2022-05-18
ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
Constellation Pharmaceuticals
Phase 1 Completed
NCT03271047 2022-01-04
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Pfizer
Phase 2 Completed
NCT01750983 2019-02-25
Ipilimumab and Lenalidomide in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01750580 2015-07-22
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
Bristol-Myers Squibb
Phase 1 Completed